VEGFA and neoplasm: Coadministration of immune checkpoint inhibitors can then harness this immunostimulatory microenvironment to more effectively target and destroy cancer cells.[13] As VEGF and immune checkpoints govern distinct but complementary tumor immune responses, it is conceivable that dual blockade of these targets results in a synergistic effect that may overcome resistance to immune checkpoint inhibition alone.